1
|
Chernyshov PV, Finlay AY, Tomas-Aragones L, Steinhoff M, Manolache L, Pustisek N, Dessinioti C, Svensson A, Marron SE, Bewley A, Salavastru C, Dréno B, Suru A, Koumaki D, Linder D, Evers AWM, Abeni D, Augustin M, Salek SS, Nassif A, Bettoli V, Szepietowski JС, Zouboulis CC. Quality of life measurement in rosacea. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol 2023; 37:954-964. [PMID: 36744752 DOI: 10.1111/jdv.18918] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Accepted: 01/16/2023] [Indexed: 02/07/2023]
Abstract
The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa (ARHS) do not recommend the use of any generic instrument as a single method of Health Related (HR) QoL assessment in rosacea, except when comparing quimp (quality of life impairment) in rosacea patients with that in other non-dermatologic skin diseases and/or healthy controls. The EADV TFs on QoL and Patient-Oriented Outcomes and ARHS recommend the use of the dermatology-specific HRQoL instrument the Dermatology Life Quality Index (DLQI) and the rosacea-specific HRQoL instrument RosaQoL in rosacea patients. The DLQI minimal clinically important difference may be used as a marker of clinical efficacy of the treatment and DLQI score banding of 0 or 1 corresponding to no effect on patients' HRQoL could be an important treatment goal. This information may be added to consensuses and guidelines for rosacea.
Collapse
Affiliation(s)
- P V Chernyshov
- Department of Dermatology and Venereology, National Medical University, Kiev, Ukraine
| | - A Y Finlay
- Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK
| | - L Tomas-Aragones
- Department of Psychology, University of Zaragoza, Zaragoza, Spain
| | - M Steinhoff
- Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar.,Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.,Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.,Weill Cornell Medicine-Qatar, Doha, Qatar.,Medical School, Qatar University, Doha, Qatar.,School of Medicine, Weill Cornell University, New York, New York, USA
| | - L Manolache
- Dermatology, Dali Medical, Bucharest, Romania
| | - N Pustisek
- Children's Hospital Zagreb, Zagreb, Croatia
| | - C Dessinioti
- Department of Dermatology, Andreas Syggros Hospital, University of Athens, Athens, Greece
| | - A Svensson
- Department of Dermatology and Venereology, Skane University Hospital, Malmö, Sweden
| | - S E Marron
- Department of Dermatology, Royo Villanova Hospital, Aragon Psychodermatology Research Group (GAI+PD), Zaragoza, Spain
| | - A Bewley
- Whipps Cross University Hospital, London, UK.,The Royal London Hospital, London, UK
| | - C Salavastru
- Department of Paediatric Dermatology, Colentina Clinical Hospital, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
| | - B Dréno
- INSERM, Immunology and New Concepts in ImmunoTherapy, INCIT, Nantes Université, Univ Angers, Nantes, France
| | - A Suru
- Department of Paediatric Dermatology, Colentina Clinical Hospital, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
| | - D Koumaki
- Department of Dermatology and Venereology, University Hospital of Heraklion, Heraklion, Crete, Greece
| | - D Linder
- University Clinic for Medical Psychology and Psychotherapy, Medical University of Graz, Graz, Austria
| | - A W M Evers
- Institute of Psychology, Health, Medical, and Neuropsychology Unit, Leiden University, Leiden, The Netherlands
| | - D Abeni
- Clinical Epidemiology Unit, IDI-IRCCS, Rome, Italy
| | - M Augustin
- Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - S S Salek
- School of Life & Medical Sciences, University of Hertfordshire, Hatfield, UK
| | | | - V Bettoli
- Department of Medical Sciences, Section of Dermatology, University of Ferrara, Ferrara, Italy
| | - J С Szepietowski
- Department of Dermatology, Wroclaw Medical University, Wroclaw, Poland
| | - C C Zouboulis
- Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany
| |
Collapse
|
2
|
Leccia MT, Claudel JP, Ballanger F, Auffret N, Dréno B. Inflammatory papules on the face are not always signs of acne. J Eur Acad Dermatol Venereol 2022; 36:e930-e931. [PMID: 35758519 DOI: 10.1111/jdv.18370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- M-T Leccia
- Department of Dermatology, Allergology and Photobiology, CHU A Michallon, Grenoble, France
| | | | | | | | - B Dréno
- Nantes Université, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, Nantes, France
| |
Collapse
|
3
|
Auffret N, Ngyen JM, Leccia MT, Claudel JP, Dréno B. TRASS: a global approach to assess the severity of truncal acne. J Eur Acad Dermatol Venereol 2022; 36:897-904. [PMID: 35170810 DOI: 10.1111/jdv.18009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Revised: 12/07/2021] [Accepted: 01/07/2022] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Only a small amount of published data regarding truncal acne is available and no proper tool to assess its severity exists. AIM to provide dermatologists with an easy-to-use tool to assess truncal acne (TRASS, truncal acne severity scale) using a global approach. METHODS A scoring tool that assesses the severity of acne (based on GEA and ECLA scales) on the trunk using a global approach was built, including three subscores: family history, clinical signs and quality of life (QoL). In order to test TRASS, the experts used photos of 47 patients attending their clinics with truncal acne. The ROP (Regression OPtimized) model was applied to assess the diagnosis performance of TRASS and to identify items contributing to the classification of the patients. Internal testing was made to demonstrate the robustness of the model. Correlation analyses between the different items were performed to evaluate the interaction between the different items and their impact on the severity grading of truncal acne. RESULTS Patients with the most severe acne were identified by TRASS. The error level was 6.6% after internal validation and 10.4% when using the median value or the centile 75th (6.6% and 10.4%). Correlation was significant between systemic treatment and scars (p=0.0025) and nodules (p=0.01988) and between location and QoL (p=0.0095). CONCLUSION TRASS is the first global, patient-centred approach to evaluate truncal acne by scoring the importance of each factor independently from its clinical severity. TRASS may allow the practitioner to choose and validate the most suitable therapy together with the patient in order to treat his or her truncal acne successfully and to limit treatment failure.
Collapse
Affiliation(s)
| | - J M Ngyen
- Biostatistic and Epidemiology, Inserm U1232, Nantes, France
| | - Marie-Thérèse Leccia
- Department of Dermatology, Allergology and Photobiology, CHU A Michallon, Grenoble, France
| | | | - B Dréno
- UF dermato-cancérologie, CHU Nantes-Hôtel-Dieu, CIC Biothérapie Inserm 05031, Inserm, U1232, Nantes, France
| |
Collapse
|
4
|
Monnet P, Herms F, Djermane M, Dalac S, Dereure O, Dréno B, Beylot-Barry M, Mortier L, Basset-Seguin N. Characterization of patients with advanced basal cell carcinoma progressing while receiving Hedgehog pathway inhibitors. Br J Dermatol 2021; 186:579-581. [PMID: 34817864 DOI: 10.1111/bjd.20808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2021] [Revised: 09/30/2021] [Accepted: 10/09/2021] [Indexed: 11/30/2022]
Affiliation(s)
- P Monnet
- Dermatology Department, AP-HP, Saint-Louis Hospital, Paris, France
| | - F Herms
- Dermatology Department, AP-HP, Saint-Louis Hospital, Paris, France.,CARADERM (Cancers RAres en DERMatologie), Lille, France
| | - M Djermane
- Dermatology Department, AP-HP, Saint-Louis Hospital, Paris, France.,CARADERM (Cancers RAres en DERMatologie), Lille, France
| | - S Dalac
- CARADERM (Cancers RAres en DERMatologie), Lille, France.,Dermatology Department, Dijon Bourgogne University Hospital, Dijon, France
| | - O Dereure
- CARADERM (Cancers RAres en DERMatologie), Lille, France.,Dermatology Department, Montpellier University Hospital, Montpellier, France
| | - B Dréno
- CARADERM (Cancers RAres en DERMatologie), Lille, France.,Dermatology Department, Nantes University Hospital, Nantes, France
| | - M Beylot-Barry
- CARADERM (Cancers RAres en DERMatologie), Lille, France.,Dermatology Department, Saint-André Hospital, Bordeaux, France
| | - L Mortier
- CARADERM (Cancers RAres en DERMatologie), Lille, France.,Dermatology Department, Lille University Hospital, Lille, France
| | - N Basset-Seguin
- Dermatology Department, AP-HP, Saint-Louis Hospital, Paris, France.,CARADERM (Cancers RAres en DERMatologie), Lille, France
| |
Collapse
|
5
|
Ruffier d'Epenoux L, Guillouzouic A, Bémer P, Dagnelie MA, Khammari A, Dréno B, Corvec S. Should we consider broad-spectrum quinolone antibacterial agent as acne treatment in the antimicrobial resistance era? J Eur Acad Dermatol Venereol 2021; 36:e193-e195. [PMID: 34626030 DOI: 10.1111/jdv.17727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- L Ruffier d'Epenoux
- Service de Bactériologie et des Contrôles Microbiologiques, CHU Nantes, Nantes, France.,CRCINA, INSERM U1232, Université de Nantes, Nantes, France
| | - A Guillouzouic
- Service de Bactériologie et des Contrôles Microbiologiques, CHU Nantes, Nantes, France
| | - P Bémer
- Service de Bactériologie et des Contrôles Microbiologiques, CHU Nantes, Nantes, France
| | - M-A Dagnelie
- CRCINA, INSERM U1232, Université de Nantes, Nantes, France
| | - A Khammari
- CRCINA, INSERM U1232, Université de Nantes, Nantes, France.,Service de Dermatologie, CHU Nantes, Nantes, France
| | - B Dréno
- CRCINA, INSERM U1232, Université de Nantes, Nantes, France.,Service de Dermatologie, CHU Nantes, Nantes, France
| | - S Corvec
- Service de Bactériologie et des Contrôles Microbiologiques, CHU Nantes, Nantes, France.,CRCINA, INSERM U1232, Université de Nantes, Nantes, France
| |
Collapse
|
6
|
Svane IM, Santos J, Cervera-Carrascon V, Havunen R, Sorsa S, Ellebæk E, Monberg T, Donia M, Khammari A, Dréno B, Hemminki A. 1032TiP A phase I, first-in-human, study of TILT-123, a tumor-selective oncolytic adenovirus encoding TNFa and IL-2, in participants with advanced melanoma receiving adoptive T-cell therapy with tumor-infiltrating lymphocytes. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1416] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
7
|
Passeron T, Lim HW, Goh CL, Kang HY, Ly F, Morita A, Ocampo Candiani J, Puig S, Schalka S, Wei L, Dréno B, Krutmann J. Photoprotection according to skin phototype and dermatoses: practical recommendations from an expert panel. J Eur Acad Dermatol Venereol 2021; 35:1460-1469. [PMID: 33764577 PMCID: PMC8252523 DOI: 10.1111/jdv.17242] [Citation(s) in RCA: 46] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Accepted: 03/10/2021] [Indexed: 12/14/2022]
Abstract
Increasing evidence on the impact of the different wavelengths of sunlight on the skin demonstrates the need for tailored recommendations of sunscreen according to skin phototype and dermatoses, which is now possible due to advances in the filters and formulations of sunscreens. A selective literature search was performed by an international expert panel, focusing on the type of sunscreen to recommend for photoaging, skin cancers, photodermatoses, pigmentary disorders and skin inflammatory disorders. Protection against ultraviolet (UV)B is especially important for light skin as there is a high risk of sunburn, DNA damage and skin cancers. Darker skin may be naturally better protected against UVB but is more prone to hyperpigmentation induced by visible light (VL) and UVA. Protection against UVA, VL and infrared A can be helpful for all skin phototypes as they penetrate deeply and cause photoaging. Long‐wave UVA1 plays a critical role in pigmentation, photoaging, skin cancer, DNA damage and photodermatoses. Adapting the formulation and texture of the sunscreen to the type of skin and dermatoses is also essential. Practical recommendations on the type of sunscreen to prescribe are provided to support the clinician in daily practice.
Collapse
Affiliation(s)
- T Passeron
- Department of Dermatology, Côte d'Azur University, Nice University Hospital Center, Nice, France.,INSERM U1065, C3M, Côte d'Azur University, Nice, France
| | - H W Lim
- Department of Dermatology, Henry Ford Health System, Detroit, MI, USA
| | - C-L Goh
- National Skin Centre, Singapore, Singapore
| | - H Y Kang
- Department of Dermatology, Ajou University School of Medicine, Suwon, South Korea
| | - F Ly
- Department of Dermatology, Cheikh Anta Diop Dakar University, EPS Institute of Social Hygiene, Dakar, Senegal
| | - A Morita
- Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - J Ocampo Candiani
- Department of Dermatology, Medical Faculty University Hospital of Nuevo León, Monterrey, Mexico
| | - S Puig
- Melanoma Unit, Dermatology Department, Barcelona University Hospital Clinic, Barcelona, Spain
| | - S Schalka
- Medcin Skin Research Center and Biochemistry Department, Chemistry Institute of São Paulo University, São Paulo, Brazil
| | - L Wei
- Department of Dermatology, The General Hospital of Air Force PLA, Beijing, China
| | - B Dréno
- Department of Dermato-Oncology, CIC 1413, CRCINA, Nantes University Hospital Center, Nantes, France
| | - J Krutmann
- IUF Leibniz Research Institute for Environmental Medicine, Dusseldorf, Germany.,Medical Faculty, Heinrich-Heine-University, Dusseldorf, Germany
| |
Collapse
|
8
|
Juzot C, Sibaud V, Amatore F, Mansard S, Seta V, Jeudy G, Pham-Ledard A, Benzaquen M, Peuvrel L, Le Corre Y, Lesage C, Viguier M, Baroudjian B, Dréno B, Quéreux G. Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study. J Eur Acad Dermatol Venereol 2021; 35:e511-e514. [PMID: 33783881 DOI: 10.1111/jdv.17253] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- C Juzot
- Department of Dermatology, Nantes University Hospital, Nantes, France
| | - V Sibaud
- Oncodermatology, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France
| | - F Amatore
- Department of dermatology, Timone Hospital, Aix-Marseille University, Marseille, France
| | - S Mansard
- Department of Dermatology, University Hospital Estaing, Clermont Ferrand, France
| | - V Seta
- Department of Dermatology, Cochin University Hospital, Paris, France
| | - G Jeudy
- Department of Dermatology, Dijon University Hospital, Dijon, France
| | - A Pham-Ledard
- Inserm U1053, Department of Dermatology, Bordeaux University Hospital, University of Bordeaux, Bordeaux, France
| | - M Benzaquen
- Department of Dermatology, Hôpital Nord, Aix-Marseille University, Marseille, France
| | - L Peuvrel
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France
| | - Y Le Corre
- Department of Dermatology, Angers University Hospital, Angers, France
| | - C Lesage
- Department of Dermatology, Montpellier University Hospital, Montpellier, France
| | - M Viguier
- Department of Dermatology, Robert Debré University Hospital, Reims University, Reims, France
| | - B Baroudjian
- Department of Dermatology, Saint-Louis University Hospital, Paris, France
| | - B Dréno
- Department of Dermatology, CIC 1413, CRCINA, Nantes University Hospital, Nantes, France
| | - G Quéreux
- Department of Dermatology, CIC 1413, CRCINA, Nantes University Hospital, Nantes, France
| |
Collapse
|
9
|
Funck-Brentano E, Malissen N, Roger A, Lebbé C, Deilhes F, Frénard C, Dréno B, Meyer N, Grob JJ, Tétu P, Saiag P. Which adjuvant treatment for patients with BRAF V600-mutant cutaneous melanoma? Ann Dermatol Venereol 2021; 148:145-155. [PMID: 33579557 DOI: 10.1016/j.annder.2020.11.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2020] [Revised: 10/22/2020] [Accepted: 11/05/2020] [Indexed: 12/21/2022]
Abstract
Treatment of patients with melanoma has considerably improved over the past decade and more recently with adjuvant therapies for patients with American Joint Committee on Cancer (AJCC) stage III (loco-regional metastases) or IV (distant metastases) totally resected melanoma, in order to prevent recurrence. In the adjuvant setting, two options are available to patients with BRAFV600-mutant AJCC stage III totally resected melanoma: anti-PD-1 blockers (nivolumab or pembrolizumab) or BRAF plus MEK inhibitors (dabrafenib plus trametinib). In the absence of comparative studies, it is difficult to determine which of these options is best. Our aim was to review published studies focusing on the management of patients with BRAFV600-mutant melanoma in the adjuvant setting. We also reviewed the main clinical trials of BRAF plus MEK inhibitors and immunotherapy in advanced (i.e. unresectable metastatic) BRAF-mutant melanoma in an attempt to identify results potentially affecting the management of patients on adjuvants. More adverse events are observed with targeted therapy, but all resolve rapidly upon drug discontinuation, whereas with immune checkpoint blockers some adverse events may persist. New therapeutic strategies are emerging, notably neoadjuvant therapies for stage III patients and adjuvant therapies for stage II patients; the place of the adjuvant strategy amidst all these options will soon be re-evaluated. The choice of adjuvant treatment could influence the choice of subsequent treatments in neo-adjuvant or metastatic settings. This review will lead clinicians to a better understanding of the different adjuvant treatments available for patients with totally resected AJCC stage III and IV BRAFV600-mutant melanoma before considering subsequent treatment strategies.
Collapse
Affiliation(s)
- E Funck-Brentano
- Department of General and Oncologic Dermatology, Ambroise-Paré hospital, AP-HP, Boulogne-Billancourt, France; Research unit EA4340 "Biomarkers and clinical trials in oncology and onco-hematology", Versailles-Saint-Quentin-en-Yvelines University, Paris-Saclay University, France.
| | - N Malissen
- Department of Dermatology and Skin Cancer, Aix-Marseille University, AP-HM, Hôpital Timone, Marseille, France
| | - A Roger
- Department of General and Oncologic Dermatology, Ambroise-Paré hospital, AP-HP, Boulogne-Billancourt, France; Research unit EA4340 "Biomarkers and clinical trials in oncology and onco-hematology", Versailles-Saint-Quentin-en-Yvelines University, Paris-Saclay University, France
| | - C Lebbé
- Inserm U976, Department of Dermatology, Dermatology, Paris University, Hôpital Saint-Louis, AP-HP, Paris, France
| | - F Deilhes
- Dermatology Department, CHU de Toulouse, Toulouse, France
| | - C Frénard
- Department of Dermatology, CRCINA, CIC1413, CHU de Nantes, université de Nantes, Nantes, France
| | - B Dréno
- Department of Dermatology, CRCINA, CIC1413, CHU de Nantes, université de Nantes, Nantes, France
| | - N Meyer
- Dermatology Department, CHU de Toulouse, Toulouse, France
| | - J-J Grob
- Department of Dermatology and Skin Cancer, Aix-Marseille University, AP-HM, Hôpital Timone, Marseille, France
| | - P Tétu
- Department of Dermatology, CRCINA, CIC1413, CHU de Nantes, université de Nantes, Nantes, France
| | - P Saiag
- Department of General and Oncologic Dermatology, Ambroise-Paré hospital, AP-HP, Boulogne-Billancourt, France; Research unit EA4340 "Biomarkers and clinical trials in oncology and onco-hematology", Versailles-Saint-Quentin-en-Yvelines University, Paris-Saclay University, France
| |
Collapse
|
10
|
Dréno B, Khammari A, Seité S, Legrand C, Halioua B, Misery L, Ezzedine K, Shourick J, Taieb C. Impact of acne on the daily life of adult patients: building a self-administered patient questionnaire. J Eur Acad Dermatol Venereol 2021; 35:1212-1218. [PMID: 33506539 DOI: 10.1111/jdv.17134] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Accepted: 12/10/2020] [Indexed: 12/12/2022]
Abstract
BACKGROUND Acne is a long-lasting disease in adolescents and adults impacting the patient's daily life. Currently, there is no specific questionnaire that assesses its impact in adult patients. AIM To build a self-administered questionnaire assessing the impact of acne on the daily life in adult patients. METHOD A multidisciplinary working group was created, including 3 experts in healthcare questionnaires and dermatologists specialized in acne. A questionnaire using a standardized methodology for designing self-administered patient questionnaires according to conceptual, development and validation phases was developed. A cultural and linguistic validation into US English was conducted, based on the original French version. RESULTS A 14-item questionnaire demonstrating consistency, reproducibility and high reliability was build. The questionnaire significantly correlated with the SF-12 mental and SF-12 physical scores and CADI, indicating good external validity. CONCLUSION The present acne burden questionnaire AI-ADL allows the practioner to assess quickly and easily the burden of acne in patients during his daily clinical practice. Moreover, its short format allows patients to express easily and quickly their feelings and to initiate a conversation between the practioner and his patient. Thus, AI-ADL may help to better understand the multidimensional nature of acne, as well as the individual impact on the acne patient's daily life and moreover, it may play a key role in the decision-making process of treatment initiation and involvement of the patient in the management of his acne.
Collapse
Affiliation(s)
- B Dréno
- Department of Oncodermatology, CHU Nantes, CRCINA, Inserm 1232, CIC 1413, University of Nantes, Nantes, France
| | - A Khammari
- Department of Oncodermatology, CHU Nantes, CRCINA, Inserm 1232, CIC 1413, University of Nantes, Nantes, France
| | - S Seité
- La Roche Posay Dermatological Laboratories, Levallois Perret, France
| | - C Legrand
- France Acné- Adolescents- Adultes, France3A, Association française de Patients, Vincennes, France
| | | | - L Misery
- Dermatology and Venerology Department, University Hospital, Brest, France
| | | | - J Shourick
- Department of Epidemiology, Hôpital de Toulouse, Toulouse, France
| | - C Taieb
- Patient-Priority, European Market Maintenance Assessment, Fontenay sous Bois, France
| |
Collapse
|
11
|
Dietrich E, Le Corre Y, Dupin N, Dréno B, Cartier I, Granry JC, Martin L. Benefits of simulation using standardized patients for training dermatology residents in breaking bad news. Ann Dermatol Venereol 2021; 148:156-160. [PMID: 33487487 DOI: 10.1016/j.annder.2020.11.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2020] [Revised: 09/29/2020] [Accepted: 11/17/2020] [Indexed: 10/22/2022]
Abstract
INTRODUCTION Simulation in healthcare is a rapidly developing teaching method in the training of technical procedures. It is also used to enable caregivers to learn how to inform patients of serious illness and complex health status. However, its use is not widespread in the field of dermatology. This study investigated the utility of simulation as regards disclosing melanoma diagnosis, taking resident physician satisfaction as a primary endpoint. MATERIALS AND METHODS Fifteen dermatology residents were recruited as trainees. Four scenarios were allocated based on length of residency. An introductory briefing was held prior to the training sessions. Debriefing took place on completion of the diagnosis disclosure consultation. The participants completed questionnaires after the simulation session, after debriefing, and 3 months after the simulation session. The primary endpoint was usefulness of the session felt by trainees several months after the simulation. RESULTS The majority of participants (93.3%) thought the session helped with stress management, improved their attitude and control over their reaction (86.6%), and improved their communication skills (100%). They rated the usefulness of the simulation at 7.79/10 on average (range: 5-10). DISCUSSION According to our findings the resident physicians involved, particularly those with the least experience, were satisfied with this type of learning technique. Any difficulties encountered by these residents were brought to light and addressed during debriefing. CONCLUSION There would appear to be real benefits to be reaped from simulation, whatever the stage of medical training at which it takes place. Simulation should become an increasingly important part of contemporary pregraduate specialty programs.
Collapse
Affiliation(s)
- E Dietrich
- Department of Dermatology, Angers University Hospital, 4, rue Larrey, 49100 Angers, France
| | - Y Le Corre
- Department of Dermatology, Angers University Hospital, 4, rue Larrey, 49100 Angers, France
| | - N Dupin
- Department of Dermatology, Angers University Hospital, 4, rue Larrey, 49100 Angers, France
| | - B Dréno
- Department of Dermatology, Tarnier University Hospital (Paris), 89, rue d'Assas, 75005 Paris, France
| | - I Cartier
- Department of Dermatology, Nantes University Hospital, 1, place Alexis-Ricordeau, 44093 Nantes, France
| | - J-C Granry
- Psychology Unit, Cancerology Coordination Center, 4, rue Larrey, 49100 Angers, France
| | - L Martin
- Department of Dermatology, Angers University Hospital, 4, rue Larrey, 49100 Angers, France; All'Sims Healthcare Simulation Center, 4, rue Larrey, 49100 Angers, France.
| |
Collapse
|
12
|
Gogas H, Dréno B, Larkin J, Demidov L, Stroyakovskiy D, Eroglu Z, Francesco Ferrucci P, Pigozzo J, Rutkowski P, Mackiewicz J, Rooney I, Voulgari A, Troutman S, Pitcher B, Guo Y, Yan Y, Castro M, Mulla S, Flaherty K, Arance A. Cobimetinib plus atezolizumab in BRAF V600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. Ann Oncol 2020; 32:384-394. [PMID: 33309774 DOI: 10.1016/j.annonc.2020.12.004] [Citation(s) in RCA: 67] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Revised: 12/01/2020] [Accepted: 12/02/2020] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND Emerging data suggest that the combination of MEK inhibitors and immunotherapeutic agents may result in improved efficacy in melanoma. We evaluated whether combining MEK inhibition and immune checkpoint inhibition was more efficacious than immune checkpoint inhibition alone in patients with previously untreated BRAFV600 wild-type advanced melanoma. PATIENTS AND METHODS IMspire170 was an international, randomized, open-label, phase III study. Patients were randomized 1 : 1 to receive cobimetinib (60 mg, days 1-21) plus anti-programmed death-ligand 1 atezolizumab (840 mg every 2 weeks) in 28-day cycles or anti-programmed death-1 pembrolizumab (200 mg every 3 weeks) alone until loss of clinical benefit, unacceptable toxicity, or consent withdrawal. The primary outcome was progression-free survival (PFS), assessed by an independent review committee in the intention-to-treat population. RESULTS Between 11 December 2017, and 29 January 2019, 446 patients were randomized to receive cobimetinib plus atezolizumab (n = 222) or pembrolizumab (n = 224). Median follow-up was 7.1 months [interquartile range (IQR) 4.8-9.9] for cobimetinib plus atezolizumab and 7.2 months (IQR 4.9-10.1) for pembrolizumab. Median PFS was 5.5 months [95% confidence interval (CI) 3.8-7.2] with cobimetinib plus atezolizumab versus 5.7 months (95% CI 3.7-9.6) with pembrolizumab [stratified hazard ratio 1.15 (95% CI 0.88-1.50); P = 0.30]. Hazard ratios for PFS were consistent across prespecified subgroups. In exploratory biomarker analyses, higher tumor mutational burden was associated with improved clinical outcomes in both treatment arms. The most common grade 3-5 adverse events (AEs) were increased blood creatine phosphokinase (10.0% with cobimetinib plus atezolizumab versus 0.9% with pembrolizumab), diarrhea (7.7% versus 1.9%), rash (6.8% versus 0.9%), hypertension (6.4% versus 3.7%), and dermatitis acneiform (5.0% versus 0). Serious AEs occurred in 44.1% of patients with cobimetinib plus atezolizumab and 20.8% with pembrolizumab. CONCLUSION Cobimetinib plus atezolizumab did not improve PFS compared with pembrolizumab monotherapy in patients with BRAFV600 wild-type advanced melanoma.
Collapse
Affiliation(s)
- H Gogas
- First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
| | - B Dréno
- Dermatology Department, CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, France
| | - J Larkin
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - L Demidov
- N.N. Blokhin Russian Cancer Research Center, Ministry of Health, Moscow, Russia
| | - D Stroyakovskiy
- Moscow City Oncology Hospital #62 of Moscow Healthcare Department, Moscow Oblast, Russia
| | - Z Eroglu
- Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
| | | | - J Pigozzo
- Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - P Rutkowski
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - J Mackiewicz
- Department of Medical and Experimental Oncology, Poznan University of Medical Sciences, and Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Center, Poznan, Poland
| | - I Rooney
- Genentech, Inc., South San Francisco, USA
| | - A Voulgari
- Roche Products Ltd, Welwyn Garden City, UK
| | - S Troutman
- Genentech, Inc., South San Francisco, USA
| | - B Pitcher
- Hoffmann-La Roche Ltd., Mississauga, Canada
| | - Y Guo
- Genentech, Inc., South San Francisco, USA
| | - Y Yan
- Genentech, Inc., South San Francisco, USA
| | - M Castro
- Genentech, Inc., South San Francisco, USA
| | - S Mulla
- Hoffmann-La Roche Ltd., Mississauga, Canada
| | - K Flaherty
- Massachusetts General Hospital Cancer Center, Boston, USA
| | - A Arance
- Department of Medical Oncology and IDIBAPS, Hospital Clínic Barcelona, Barcelona, Spain
| |
Collapse
|
13
|
Charpentier C, Riche VP, Guilé R, Varey É, Fronteau C, Flet L, Thomare P, Poinas A, Khammari A, Dréno B. Étude comparative médico-économique des approches par chimiothérapie versus nouvelles thérapies anticancéreuses dans le mélanome de stade IIIC/IV. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
14
|
Maubec E, Boubaya M, Petrow P, Beylot-Barry M, Basset-Seguin N, Deschamps L, Grob J, Dréno B, Scheer-Senyarich I, Bloch-Queyrat C, Leccia MT, Stefan A, Saiag P, Grange F, Meyer N, de Quatrebarbes J, Dinulescu M, Legoupil D, Machet L, Dereure O, Zehou O, Montaudié H, Wierzbicka-Hainaut E, Le Corre Y, Mansard S, Guegan S, Arnault JP, Dalac S, Aubin F, Alloux C, Lopez I, Cherbal S, Tibi A, Dalac S, Levy V. Étude de phase II de l’administration de pembrolizumab (MK-3475) en monothérapie et en première ligne chez des patients présentant un carcinome épidermoïde cutané non opérable. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
15
|
Ah-Thiane L, Samimi M, Kervarrec T, Khammari A, Dréno B. Carcinome de Merkel spontanément régressif de la face : caractérisation des lymphocytes intra-tumoraux avant et après régression. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
16
|
Rousseau P, Masson D, Bach-Ngohou K, Nguyen J, Le Moigne M, Bregeon B, Khammari A, Dréno B. Maladie de Verneuil et statut IGF1. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
17
|
Khammari A, Dinulescu M, Nguyen JM, Cassecuel J, Maillard H, Le Duff F, Machet L, Beylot-Barry M, Legoupil D, Wierzbicka-Hainaut E, Bedane C, Leccia MT, Debarbieux S, Meyer N, Monestier S, Bens G, Denis M, Vourch M, Bossard C, Vergier B, Dréno B. L’efficacité de l’imiquimod dans la prise en charge du mélanome de Dubreuilh in situ (lentigo malin). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
18
|
Juzot C, Sibaud V, Amatore F, Mansard S, Seta V, Jeudy G, Pham-Ledard A, Benzaquen M, Dinulescu M, Le Corre Y, Lesage C, Viguier M, Baroudjian B, Clerc CJ, Funck-Brentano E, Giacchero D, Mortier L, Peuvrel L, Machet L, Duvert-Lehembre S, Viarnaud A, Joachim C, Bara C, Baubion E, Bergeret B, Brunet-Possenti F, Debarbieux S, Hébert V, Konstantinou MP, Marzouki-Zerouali A, Moreau-Huguen J, Phan C, Templier I, Celerier P, Aubin F, Modiano P, Poinas A, Vibet MA, Dréno B, Quéreux G. Pemphigoïdes bulleuses associées aux anti-PD-1/PDL-1 : étude nationale de 85 cas. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.123] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
19
|
Khammari A, Nguyen JM, Leccia MT, Guillot B, Saiagh S, Pandolfino MC, Frénard C, Chiffoleau A, Quereux-Baumgartner G, Labarrière N, Dréno B. TIL en adjuvant chez des patients au stade III du mélanome avec un seul ganglion envahi. Étude multicentrique de phase III. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
20
|
Paugam C, Dréno B. Is nicotinamide a sustainable therapy for resistant actinic keratoses? J Eur Acad Dermatol Venereol 2020; 34:e624-e626. [DOI: 10.1111/jdv.16501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- C. Paugam
- Department of Dermatology University Hospital Nantes Nantes France
| | - B. Dréno
- Department of Dermatology University Hospital Nantes Nantes France
| |
Collapse
|
21
|
Garbe C, Peris K, Soura E, Forsea AM, Hauschild A, Arenbergerova M, Bylaite M, Del Marmol V, Bataille V, Samimi M, Gandini S, Saiag P, Eigentler TK, Lallas A, Zalaudek I, Lebbe C, Grob JJ, Hoeller C, Robert C, Dréno B, Arenberger P, Kandolf-Sekulovic L, Kaufmann R, Malvehy J, Puig S, Leiter U, Ribero S, Papadavid E, Quaglino P, Bagot M, John SM, Richard MA, Trakatelli M, Salavastru C, Borradori L, Marinovic B, Enk A, Pincelli C, Ioannides D, Paul C, Stratigos AJ. The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force. J Eur Acad Dermatol Venereol 2020; 34:2183-2197. [PMID: 32840022 DOI: 10.1111/jdv.16849] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Accepted: 07/13/2020] [Indexed: 12/17/2022]
Abstract
BACKGROUND The incidence of skin cancers has been increasing steadily over the last decades. Although there have been significant breakthroughs in the management of skin cancers with the introduction of novel diagnostic tools and innovative therapies, skin cancer mortality, morbidity and costs heavily burden the society. OBJECTIVE Members of the European Association of Dermato-Oncology, European Academy of Dermatology and Venereology, International Dermoscopy Society, European Dermatology Forum, European Board of Dermatovenereology of the European Union of Medical Specialists and EORTC Cutaneous Lymphoma Task Force have joined this effort to emphasize the fundamental role that the specialist in Dermatology-Venereology has in the diagnosis and management of different types of skin cancer. We review the role of dermatologists in the prevention, diagnosis, treatment and follow-up of patients with melanoma, non-melanoma skin cancers and cutaneous lymphomas, and discuss approaches to optimize their involvement in effectively addressing the current needs and priorities of dermato-oncology. DISCUSSION Dermatologists play a crucial role in virtually all aspects of skin cancer management including the implementation of primary and secondary prevention, the formation of standardized pathways of care for patients, the establishment of specialized skin cancer treatment centres, the coordination of an efficient multidisciplinary team and the setting up of specific follow-up plans for patients. CONCLUSION Skin cancers represent an important health issue for modern societies. The role of dermatologists is central to improving patient care and outcomes. In view of the emerging diagnostic methods and treatments for early and advanced skin cancer, and considering the increasingly diverse skills, knowledge and expertise needed for managing this heterogeneous group of diseases, dermato-oncology should be considered as a specific subspecialty of Dermatology-Venereology.
Collapse
Affiliation(s)
- C Garbe
- Center for Dermato-oncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany
| | - K Peris
- Dermatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.,Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy
| | - E Soura
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodestrian University of Athens, Athens, Greece
| | - A M Forsea
- Department of Oncologic Dermatology, University Hospital Elias, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - A Hauschild
- Department of Dermatology, University of Kiel, Kiel, Germany
| | - M Arenbergerova
- Department of Dermatovenereology, Third Faculty of Medicine, Charles University, University Hospital of Kralovske Vinohrady, Prague, Czech Republic
| | - M Bylaite
- Faculty of Medicine, Centre of Dermatovenereology, Clinic of Infectious Diseases and Dermatovenereology, Vilnius University, Vilnius, Lithuania
| | - V Del Marmol
- Dermatology Department, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - V Bataille
- Dermatology Department, West Herts NHS Trust, London, UK.,Twin Research and Genetic Epidemiology Department, Kings College London, London, UK
| | - M Samimi
- Departments of Dermatology, University Hospital of Tours, Tours, France
| | - S Gandini
- Molecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - P Saiag
- Department of General and Oncologic Dermatology, Ambroise-Paré Hospital, APHP, & EA 4340, 'Biomarkers in Cancerology and Hemato-Oncology', UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France
| | - T K Eigentler
- Departments of Dermatology, University Hospital Tübingen, Tubingen, Germany
| | - A Lallas
- First Dermatology Department, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - I Zalaudek
- Department of Dermatology, University of Trieste, Trieste, Italy
| | - C Lebbe
- Department of Dermatology, AP-HP Saint Louis Hospital, Paris, France
| | - J-J Grob
- Timone Hospital, Aix-Marseille University, Marseille, France
| | - C Hoeller
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - C Robert
- Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France.,Paris-Saclay University, Le Kremlin Bicêtre, France
| | - B Dréno
- Department of Dermatolo-Cancerology, CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, France
| | - P Arenberger
- Department of Dermatovenereology, Third Faculty of Medicine, Charles University, University Hospital of Kralovske Vinohrady, Prague, Czech Republic
| | - L Kandolf-Sekulovic
- Department of Dermatology, Faculty of Medicine, Military Medical Academy, University of Defense, Belgrade, Serbia
| | - R Kaufmann
- Department of Dermatology, Venerology and Allergology, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - J Malvehy
- Dermatology Department, Hospital Clinic of Barcelona, University of Barcelona, Spain.,Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Biomedical Research Networking Centre on rarae disease (CIBERER), ISCIII, Barcelona, Spain
| | - S Puig
- Dermatology Department, Hospital Clinic of Barcelona, University of Barcelona, Spain.,Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Biomedical Research Networking Centre on rarae disease (CIBERER), ISCIII, Barcelona, Spain
| | - U Leiter
- Center for Dermato-oncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany
| | - S Ribero
- Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
| | - E Papadavid
- 2nd Department of Dermatology-Venereology, ATTIKON Hospital, National and Kapodistrian Univeristy of Athens, Athens, Greece
| | - P Quaglino
- Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
| | - M Bagot
- Department of Dermatology, AP-HP Saint Louis Hospital, Paris, France
| | - S M John
- Department Dermatology, Environmental Medicine, Health Theory, University of Osnabrueck, Osnabrueck, Germany
| | - M-A Richard
- Timone Hospital, Aix-Marseille University, Marseille, France
| | - M Trakatelli
- 2nd Department of Dermatology-Venerology, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - C Salavastru
- Pediatric Dermatology Discipline, Dermato-oncology Research Facility, Colentina Clinical Hospital, Bucharest, Romania
| | - L Borradori
- Department of Dermatology, University Hospital of Bern, Inselspital, Bern, Switzerland
| | - B Marinovic
- Department of Dermatology and Venereology, University Hospital Center Zagreb, School of Medicine University of Zagreb, Zagreb, Croatia
| | - A Enk
- Department of Dermatology, University Hospital of Heidelberg, Heidelberg, Germany
| | - C Pincelli
- DermoLab, Dermatology, University of Modena and Reggio Emilia, Modena, Italy
| | - D Ioannides
- First Dermatology Department, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - C Paul
- Department of Dermatology, Toulouse University, Toulouse, France
| | - A J Stratigos
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodestrian University of Athens, Athens, Greece
| |
Collapse
|
22
|
Mesnard C, Bodet-Milin C, Eugène T, Nguyen JM, Khammari A, Dréno B. Predictive value of FDG-PET imaging for relapse in metastatic melanoma patients treated with immunotherapy. J Eur Acad Dermatol Venereol 2020; 34:2261-2267. [PMID: 32219890 DOI: 10.1111/jdv.16358] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Accepted: 02/25/2020] [Indexed: 12/17/2022]
Abstract
BACKGROUND Anti-PD1 immunotherapy has shown a sustainable clinical activity in patients with metastatic melanoma. However, strong predictive factors of the long-term response or risk of relapse remain to be identified. OBJECTIVES To determine whether FDG-PET imaging could be superior to CT scan in distinguishing residual tumours versus the absence of tumour in patients with a partial response (PR) or stable disease (SD) and whether a complete metabolic response (CMR) was associated with better outcomes. METHODS Retrospective study conducted in all patients with metastatic melanoma treated with anti-PD1 immunotherapy between October 2014 and October 2017 considered to be in complete remission. The primary outcome was the occurrence of a relapse during the follow-up. CT scan and FDG-PET scan had to be performed within a maximum of 2 months of treatment discontinuation. For CT imaging, the Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 were used and included progressive disease (PD), SD, PR and complete response (CR). For FDG-PET imaging, the metabolic responses were classified as progressive metabolic disease, stable metabolic disease, residual FDG avidity (RFA) and CMR. RESULTS Twenty-six patients were in complete remission after collegial decision. Two patients had a SD on CT scan and a CMR on FDG-PET scan, and none of them relapsed. Ten patients had a PR on CT scan and a CMR on FDG-PET scan, and none of them relapsed. The mean treatment duration to achieve a complete remission was 7 months (3-23). A univariate analysis showed that a RFA assessed on the FDG-PET scan was significantly associated with a relapse (P = 0.00231). CONCLUSIONS Most patients with a PR on the CT scan and a CMR on the FDG-PET scan should be considered with a CR. Our study showed that FDG-PET imaging could play a crucial role in predicting the long-term outcome and help to decide whether treatment should be discontinued.
Collapse
Affiliation(s)
- C Mesnard
- Department of Dermatology, CHU Nantes, CRCINA, Université de Nantes, Nantes, France
| | - C Bodet-Milin
- Department of Nuclear Medicine, CHU Nantes, Nantes, France.,CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | - T Eugène
- Department of Nuclear Medicine, CHU Nantes, Nantes, France.,CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
| | - J-M Nguyen
- Department of Epidemiology and Biostatistics, CHU Nantes, CRCINA, INSERM, Université de Nantes, Nantes, France
| | - A Khammari
- Department of Dermatology, CHU Nantes, CRCINA, Université de Nantes, Nantes, France
| | - B Dréno
- Department of Dermatology, CHU Nantes, CRCINA, Université de Nantes, Nantes, France
| |
Collapse
|
23
|
Pistorius MA, Blaise S, Le Hello C, Barbarot S, Dréno B. Chilblains and COVID19 infection: Causality or coincidence? How to proceed? JMV-Journal de Médecine Vasculaire 2020; 45:221-223. [PMID: 32571563 PMCID: PMC7211700 DOI: 10.1016/j.jdmv.2020.05.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/22/2020] [Accepted: 04/30/2020] [Indexed: 11/30/2022]
Affiliation(s)
- M A Pistorius
- Department of Vascular Medicine, Nantes University Hospital, 44000 Nantes, France.
| | - S Blaise
- Department of Vascular Medicine, Grenoble University Hospital, University Grenoble Alpes, 38000 Grenoble, France
| | - C Le Hello
- Department of Therapeutic and Vascular Medicine, Saint-Etienne University Hospital, inserm, U1059 Sainbiose, University de Lyon, Saint-Etienne, 42000 Saint-Etienne, France
| | - S Barbarot
- Department of Dermatology, Nantes University Hospital, 44000 Nantes, France
| | - B Dréno
- Department of Dermatology, Nantes University Hospital, 44000 Nantes, France
| |
Collapse
|
24
|
Poli F, Auffret N, Leccia MT, Claudel JP, Dréno B. Truncal acne, what do we know? J Eur Acad Dermatol Venereol 2020; 34:2241-2246. [PMID: 32421879 DOI: 10.1111/jdv.16634] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2020] [Accepted: 04/30/2020] [Indexed: 12/21/2022]
Abstract
Truncal acne is frequently overlooked in dermatological practice, even though it may result in scars and impact on self-esteem and body image. Therefore, it is important to identify the disease early in order to initiate treatment in time and, thus, to prevent it from worsening and resulting in physical and psychological sequelae. The aim of this review is to provide an overview of what is currently known about truncal acne, its prevalence, aetiology and physiopathology, how its severity is currently evaluated, how to differentiate it from other skin afflictions and current treatment options. A review of literature considering the issue of truncal acne published up to 2019 and available from PubMed was conducted, and in total, 76 articles were selected from PubMed. Currently, only little information about truncal acne is available. Considered as having the same pathophysiology as facial acne, the clinical picture and treatment response seem to differ. Specific acne severity grading systems and quality of life questionnaires as well as a specific treatment algorithm are still lacking. Filling this gap should allow clinicians to assess truncal acne in the best possible way, choosing suitable treatment options, helping patients to improve treatment adherence and quality of life and finally allowing a better management of truncal acne. In conclusion, more knowledge is required to treat more efficiently truncal acne.
Collapse
Affiliation(s)
- F Poli
- Private Practice, Paris, France
| | | | - M-T Leccia
- Department of Dermatology, Allergology and Photobiology, CHU A Michallon, Grenoble, France
| | | | - B Dréno
- UF dermato-cancérologie, CHU Nantes-Hôtel-Dieu, Inserm U1232, CIC Biothérapie Inserm 05031, Nantes, France
| |
Collapse
|
25
|
Schadendorf D, Hauschild A, Fosko S, Zloty D, Labeille B, Grob J, Puig S, Makrutzki M, Gilberg F, Hong A, Dréno B, Rogers G, Kunstfeld R. Quality‐of‐life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient‐reported outcomes from the MIKIE study. J Eur Acad Dermatol Venereol 2020; 34:e526-e529. [DOI: 10.1111/jdv.16446] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
| | - A. Hauschild
- University Hospital Schleswig‐Holstein Kiel Germany
| | - S. Fosko
- Saint Louis University Medical School St. Louis MO USA
| | - D. Zloty
- University of British Columbia Vancouver BC Canada
| | - B. Labeille
- University Hospital of Saint‐Etienne Saint‐Priest‐en‐Jarez France
| | - J.‐J. Grob
- Aix‐Marseille University Marseille France
- Timone Hospital Marseille France
| | - S. Puig
- Hospital Clinic de Barcelona University of BarcelonaIDIBAPS (Institut d’Investigacions Biomediques August Pi i Sunyer) Barcelona Spain
- Centro de Investigación Biomedica en Red de Enfermedades Raras (CIBER ER) Barcelona Spain
| | | | - F. Gilberg
- F. Hoffmann‐La Roche Ltd Basel Switzerland
| | - A. Hong
- Genentech, Inc. South San Francisco CA USA
| | | | - G. Rogers
- Tufts University School of Medicine Boston MA USA
| | | |
Collapse
|
26
|
Dréno B, Zuberbier T, Gelmetti C, Gontijo G, Marinovich M. Safety review of phenoxyethanol when used as a preservative in cosmetics. J Eur Acad Dermatol Venereol 2020; 33 Suppl 7:15-24. [PMID: 31588615 DOI: 10.1111/jdv.15944] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2019] [Accepted: 09/03/2019] [Indexed: 11/29/2022]
Abstract
Phenoxyethanol, or 2-phenoxyethanol, has a large spectrum of antimicrobial activity and has been widely used as a preservative in cosmetic products for decades. It is effective against various Gram-negative and Gram-positive bacteria, as well as against yeasts, and has only a weak inhibitory effect on resident skin flora. According to the European Scientific Committee on Consumer Safety, phenoxyethanol is safe for all consumers - including children of all ages - when used as a preservative in cosmetic products at a maximum concentration of 1%. Adverse systemic effects have been observed in toxicological studies on animals but only when the levels of exposure were many magnitudes higher (around 200-fold higher) than those to which consumers are exposed when using phenoxyethanol-containing cosmetic products. Despite its widespread use in cosmetic products, phenoxyethanol is a rare sensitizer. It can be considered as one of the most well-tolerated preservatives used in cosmetic products.
Collapse
Affiliation(s)
- B Dréno
- Dermatology Department, CHU Nantes, CIC 1413 CRCINA, University of Nantes, Nantes, France
| | - T Zuberbier
- Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - C Gelmetti
- UOC Dermatologia Pediatrica, IRCCS Fondazione Ca' Granda "Ospedale Maggiore Policlinico", Dipartimento di Fisiopatologia Medico-Chirurgica, Università degli Studi di Milano, Milan, Italy
| | - G Gontijo
- Department of Dermatology, UFMG Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - M Marinovich
- Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
| |
Collapse
|
27
|
Affiliation(s)
- B Dréno
- Dermatology department, CRCINA, University Nantes, France
| |
Collapse
|
28
|
Dréno B, Zuberbier T, Gelmetti C, Gontijo G, Marinovich M. Answer to the letter to the editor titled 'Phenoxyethanol, reproduction, and development: additional studies are needed'. J Eur Acad Dermatol Venereol 2020; 34:e409-e410. [PMID: 32145100 DOI: 10.1111/jdv.16343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Accepted: 02/18/2020] [Indexed: 11/29/2022]
Affiliation(s)
- B Dréno
- Onco-Dermatology Department, CHU Nantes, CRCINA, University Nantes, Nantes, France
| | - T Zuberbier
- Department of Dermatology and Allergy, Charité -Universitätsmedizin Berlin, Berlin, Germany
| | - C Gelmetti
- UOC Dermatologia Pediatrica, IRCCS Fondazione Ca' Granda "Ospedale Maggiore Policlinico", Dipartimento di Fisiopatologia Medico-Chirurgica, Università degli Studi di Milano, Milan, Italy
| | - G Gontijo
- Department of Dermatology, UFMG Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - M Marinovich
- Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
| |
Collapse
|
29
|
Dummer R, Ascierto P, Basset‐Seguin N, Dréno B, Garbe C, Gutzmer R, Hauschild A, Krattinger R, Lear J, Malvehy J, Schadendorf D, Grob J. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol 2020; 34:1944-1956. [DOI: 10.1111/jdv.16230] [Citation(s) in RCA: 59] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Accepted: 12/17/2019] [Indexed: 12/23/2022]
Affiliation(s)
- R. Dummer
- Department of Dermatology University Hospital of Zurich Zurich Switzerland
| | - P.A. Ascierto
- Melanoma Cancer Immunotherapy and Development Therapeutics Unit Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Naples Italy
| | | | - B. Dréno
- Department of Dermato Oncology University Hospital Nantes Nantes France
| | - C. Garbe
- Division of Dermato‐oncology University of Tübingen Tübingen Germany
| | - R. Gutzmer
- Skin Cancer Center Hannover Department of Dermatology Hannover Medical School Hannover Germany
| | - A. Hauschild
- Department of Dermatology University Hospital Schleswig‐Holstein Kiel Germany
| | - R. Krattinger
- Department of Dermatology University Hospital of Zurich Zurich Switzerland
| | - J.T. Lear
- Department of Dermatology Manchester Academic Health Science Centre Manchester University and Salford Royal NHS Trust Manchester UK
| | - J. Malvehy
- Dermatology Department Hospital Clinic of Barcelona IDIBAPS University of Barcelona Barcelona Spain
| | - D. Schadendorf
- Department of Dermatology University Hospital Essen Essen & German Cancer Consortium Heidelberg Germany
| | - J.J. Grob
- Dermatology and Oncology Service Aix Marseille University and Timone Hospital Marseille France
| |
Collapse
|
30
|
Claudel JP, Auffret N, Leccia MT, Poli F, Dréno B. Acne from the young patient's perspective. J Eur Acad Dermatol Venereol 2019; 34:942-947. [PMID: 31715036 DOI: 10.1111/jdv.16067] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2019] [Accepted: 10/31/2019] [Indexed: 12/21/2022]
Abstract
Acne may significantly impact quality of life, self-esteem and self-worth. The aim of this paper was to provide an overview of the knowledge and perception of acne and its risk factors in adolescents and young adults. The most critical issues reported for an optimal management of this specific population were identified. A PubMed literature review of results from patient-oriented surveys published between 2007 and 2018 was conducted. Two different types of survey were used: those using either validated questionnaires or specifically developed questionnaires. No consistency or directly comparable data with regards to age, onset, duration, severity and treatment of acne and by whom and where data were collected were observed. Acne affected female patients psychologically more than male patients. The majority referred to their treating physician in order to obtain information, and all surveys pointed out that specific treatment programs would allow to increase awareness about acne. Beliefs, traditions and economic factors continue to impact the perception of and treatment choices for acne in almost all countries and cultures, maintaining the improvement of awareness about acne a major global health challenge. In conclusion, identifying, considering and managing the patient's concerns about acne may improve the young patient's well-being and thus decrease additional healthcare expenses for emerging psychological comorbidities. This can be achieved by creating substantial and structured awareness through local and global information campaigns via the treating physicians, Internet, social networks and education.
Collapse
Affiliation(s)
| | | | - M-T Leccia
- Department of Dermatology, Allergology and Photobiology, CHU A Michallon, Grenoble, France
| | - F Poli
- Private Practice, Paris, France
| | - B Dréno
- UF Dermato-cancérologie, Inserm U1232, CIC Biothérapie Inserm 05031, CHU Nantes-Hôtel-Dieu, Nantes, France
| |
Collapse
|
31
|
Maubec E, Boubaya M, Petrow P, Basset-Seguin N, Grob JJ, Dréno B, Beylot-Barry M, Scheer-Senyarich I, Helfen S, Deschamps L, Leccia MT, Stefan A, Saiag P, De Quatrebarbes J, Meyer N, Alloux C, Lopez I, Cherbal S, Tibi A, Levy V. Étude de phase II de l’administration de pembrolizumab (MK-3475) en monothérapie et en première ligne chez des patients présentant un carcinome épidermoïde cutané non opérable. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Varey E, Dalle S, Dupuy A, Montaudié H, Guillot B, Mortier L, Leccia MT, Célérier P, Skowron F, Meyer N, Maubec E, Combemale P, Crickx B, Dalac-Rat S, Dutriaux C, Khammari A, Lebbé C, Dréno B. Patients présentant un mélanome acro-lentigineux inclus dans la base nationale RIC-Mel. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
33
|
Colle E, Dalle S, Mortier L, Guillot B, Dutriaux C, Leccia MT, Dalac S, Legoupil D, Dequatrebarbes J, Montaudié H, Jean-Philippe A, Brunet-Possenti F, Saiag P, Vu LT, Momenzadeh M, Allayous C, Porcher R, Oriano B, Dréno B, Lebbé C. Hyperprogression sous traitement par anti-PD-1 pour les patients ayant un mélanome de stade III non résécable ou de stade IV métastatique. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
34
|
Piroth M, Frénard C, Dréno B, Quéreux G. Panniculite sous anti-BRAF et/ou anti-MEK : le point en 2019. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
35
|
Rousseau P, Saint Jean M, Varey E, Denyset M, Khammari A, Dréno B. Caractérisation des patients atteints de mélanomes primitifs multiples au CHU de Nantes. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
36
|
Goussault R, Frenard C, Varey E, Vrignaud F, Lecerf P, Khammari A, Dréno B. Évaluation de la réponse attendue au traitement par anti-PD1 chez les patients avec un mélanome de stade IIIc-IV à l’aide de l’intelligence artificielle. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
Bagot M, Beylot-Barry M, Dréno B, Dalle S. Bénéfice clinique à long terme du mogamulizumab (anti-CCR4) : résultats post-hoc de MAVORIC, une étude de phase III menée chez des patients précédemment traités pour un lymphome T cutané. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Lorant J, Pandolfino MC, Khammari A, Dréno B. Les vésicules extracellulaires (EVs) de mélanome possèdent des propriétés immunomodulatrices. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
39
|
Dagnelie MA, Ruffier-Depenoux L, Frénard C, Khammari A, Corvec S, Dréno B. La capacité de production de biofilm des souches de Cutibacterium acnes dépend plus du type SLST que de l’origine clinique. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
40
|
Dréno B, Bouloc A, Sourick J, Kerob D, Taïeb C. Premiers résultats d’une étude acné exposome – vie réelle. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
41
|
Beylot-Barry M, Bagot M, Dréno B, Dalle S. Délai jusqu’au traitement suivant chez les patients traités pour un lymphome T cutané (LTC) recevant précédemment du mogamulizumab ou du vorinostat : une analyse post hoc de l’étude MAVORIC. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
42
|
Dréno B, Alexis A, Chuberre B, Marinovich M. Safety of titanium dioxide nanoparticles in cosmetics. J Eur Acad Dermatol Venereol 2019; 33 Suppl 7:34-46. [DOI: 10.1111/jdv.15943] [Citation(s) in RCA: 79] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2019] [Accepted: 09/03/2019] [Indexed: 12/31/2022]
Affiliation(s)
- B. Dréno
- Onco‐Dermatology Department CHU Nantes CRCINA University Nantes Nantes France
| | - A. Alexis
- Department of Dermatology Icahn School of Medicine at Mount Sinai New York NY USA
| | - B. Chuberre
- L'Oréal Cosmetique Active International Levallois‐Perret France
| | - M. Marinovich
- Department of Pharmacological and Biomolecular Sciences University of Milan Milan Italy
| |
Collapse
|
43
|
Dagnelie M, Saint-Jean M, Khammari A, Corvec S, Dréno B. 327 Severe acne and biofilm production of Cutibacterium acnes strains: Different biofilm potentials for different phylotypes. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
44
|
Dagnelie M, Montassier E, Khammari A, Mounier C, Corvec S, Dréno B. 326 Severe acne of the back is associated with modifications of the cutaneous microbiome. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
45
|
Dagnelie MA, Corvec S, Saint-Jean M, Nguyen JM, Khammari A, Dréno B. Cutibacterium acnes phylotypes diversity loss: a trigger for skin inflammatory process. J Eur Acad Dermatol Venereol 2019; 33:2340-2348. [PMID: 31299116 DOI: 10.1111/jdv.15795] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Accepted: 05/24/2019] [Indexed: 12/27/2022]
Abstract
BACKGROUND Acne has long been understood as a multifactorial chronic inflammatory disease of the pilosebaceous follicle, where Cutibacterium acnes (subdivided into six main phylotypes) is a crucial factor. In parallel, the loss of microbial diversity among the skin commensal communities has recently been shown as often accompanied by inflammatory skin disorders. OBJECTIVE This study investigated the association of C. acnes phylotype diversity loss and the impact on Innate Immune System (IIS) activation. METHODS The IIS response of skin after incubation with phylotypes IA1, II or III individually and with the combination of IA1 + II + III phylotypes, was studied in an in vitro skin explant system. The inflammatory response was monitored by immunohistochemistry and ELISA assays, targeting a selection of Innate Immune Markers (IIMs) (IL-6, IL-8, IL-10, IL-17, TGF-β). RESULTS IIMs were significantly upregulated in skin when being incubated with phylotype IA1 alone compared with the combination IA1 + II + III. In parallel, ELISA assays confirmed these results in supernatants for IL-17, IL-8 and IL-10. CONCLUSION We identify the loss of C. acnes phylotype diversity as a trigger for IIS activation, leading to cutaneous inflammation. These innovative data underline the possibility to set up new approaches to treat acne. Indeed, maintaining the balance between the different phylotypes of C. acnes may be an interesting target for the development of drugs.
Collapse
Affiliation(s)
- M-A Dagnelie
- Dermatology Department, CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, France
| | - S Corvec
- Bacteriology Department, CHU Nantes, CRCINA, University Nantes, Nantes, France
| | - M Saint-Jean
- Dermatology Department, CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, France
| | - J-M Nguyen
- Biostatistical Department, CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, France
| | - A Khammari
- Dermatology Department, CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, France
| | - B Dréno
- Dermatology Department, CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, France
| |
Collapse
|
46
|
Piroth M, Frenard C, Quereux G, Khammari A, Corvec S, Dréno B. Gut dysbiosis: not only with checkpoint inhibitors! Clin Exp Dermatol 2019; 45:247-249. [PMID: 31222907 DOI: 10.1111/ced.14018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/08/2019] [Indexed: 11/29/2022]
Affiliation(s)
- M Piroth
- Dermatology Department, CHU Nantes, University of Nantes, Nantes, France
| | - C Frenard
- Dermatology Department, CHU Nantes, University of Nantes, Nantes, France.,CRCINA, University of Nantes, Nantes, France
| | - G Quereux
- Dermatology Department, CHU Nantes, University of Nantes, Nantes, France.,CRCINA, University of Nantes, Nantes, France
| | - A Khammari
- Dermatology Department, CHU Nantes, University of Nantes, Nantes, France.,CRCINA, University of Nantes, Nantes, France
| | - S Corvec
- Bacteriology and Hygiene Department, Hôtel-Dieu, Nantes University Hospital, CRCINA, University of Nantes, Nantes, France
| | - B Dréno
- Dermatology Department, CHU Nantes, University of Nantes, Nantes, France.,CRCINA, University of Nantes, Nantes, France
| |
Collapse
|
47
|
Claudel J, Auffret N, Leccia M, Poli F, Dréno B. Reply to comments made by M. Donnarumma
et al
. Comment on “Acne and nutrition: hypotheses, myths and facts” published by our expert group in 2018. J Eur Acad Dermatol Venereol 2019; 33:e420. [DOI: 10.1111/jdv.15722] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
| | | | - M.T. Leccia
- Department of Dermatology, Allergology and Photobiology CHU A Michallon Grenoble France
| | - F. Poli
- Private Practice Paris France
| | - B. Dréno
- Department of Dermato‐Cancerology Nantes University Hospital Nantes France
| |
Collapse
|
48
|
Paugam C, Dréno B. Actualités sur la prise en charge des kératoses actiniques chez les patients transplantés d’organes. Ann Dermatol Venereol 2019; 146 Suppl 2:IIS31-IIS35. [PMID: 31133228 DOI: 10.1016/s0151-9638(19)30203-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Transplant recipients are at high risk of developing actinic keratosis (AK) and skin cancer. For this reason, initiating treatment at an early stage is crucial. Topical and systemic therapeutic options for AK have widely been described in studies of immunocompetent patients. However, little is known about AK management in organ transplant recipients (OTR). Photodynamic therapy (PDT), along with imiquimod, topical NSAIDs and topical 5-fluorouracil have been used on ORT patients in small non randomized studies. Although these studies seem to suggest that PDT offers best results, solid evidence is lacking. Nicotinamide and oral retinoids have also been described as reasonably effective preventive treatments in ORT patients. Management of immunosuppressive drugs is also considered as a key point for reducing the number of AK in ORT patients; an early switch for m-tor inhibitors has been shown to be protective while azathioprine, ciclosporin and tacrolimus have been shown to heighten the risk of developing AKs and skin cancer in this population. © 2019 Elsevier Masson SAS. All rights reserved. Cet article fait partie du numéro supplément Kératoses actiniques : comprendre et traiter réalisé avec le soutien institutionnel de Galderma International.
Collapse
Affiliation(s)
- C Paugam
- Clinique dermatologique, Hôtel-Dieu CHU de Nantes, 1 place Alexis-Ricordeau, 44035 Nantes Cedex 01, France
| | - B Dréno
- Clinique dermatologique, Hôtel-Dieu CHU de Nantes, 1 place Alexis-Ricordeau, 44035 Nantes Cedex 01, France.
| |
Collapse
|
49
|
Khammari A, Blanchet-Réthoré S, Bourdès V, Marty C, Piketty C, Dréno B. Evolution and duration of nodules in severe nodular acne on the back: results from a four-week non-interventional, prospective study. J Eur Acad Dermatol Venereol 2019; 33:601-607. [PMID: 30891846 DOI: 10.1111/jdv.15407] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2018] [Accepted: 11/14/2018] [Indexed: 11/30/2022]
Abstract
BACKGROUND Severe nodular acne is characterized by inflammatory nodules and scarring. Their natural evolution and duration are insufficiently investigated. AIM To investigate the evolution and duration of untreated acne nodules. METHODOLOGY Four-week, single-centre, non-interventional, prospective study in subjects with severe nodular acne on the back. Nodule evolution and duration was assessed using standardized photographs taken twice weekly. RESULTS Data from 23 subjects were evaluable. Mean age was 25.1 ± 4.9 years, 87% were males, and mean acne duration was 9.7 ± 6.7 years. At baseline, the overall total nodule count was 132 (mean number: 5.7 ± 3.0 nodules/subject). Among others, the following two main pathways were observed: nodules evolving directly into atrophic scars (31.8%) and nodules evolving towards papules into atrophic scars (37.9%). After 4 weeks, 77.3% of baseline nodules had evolved into atrophic scars. After baseline visit, a total of 247 new nodules (3.1 ± 2.2 nodules/week/subject) with a mean duration of 4.9 ± 2.6 days were observed. The mean duration of new nodules was significantly longer in subjects (n = 16) with ≥6 new nodules compared to subjects (n = 7) with <6 new nodules (5.2 ± 1.4 vs. 3.6 ± 0.8 days; P = 0.008)). There was no correlation between the number of new nodules and acne duration or with the number of baseline nodules. CONCLUSION This study documents the natural nodule evolution and duration over 4 weeks and showed in 23 patients the scarring potential of untreated severe nodular acne of the back.
Collapse
Affiliation(s)
- A Khammari
- Dermatology, CHU Nantes, CRCINA, University Nantes, Nantes, France
| | - S Blanchet-Réthoré
- Evaluation Department-Cutis, Galderma R&D, Nestlé Skin Health, Sophia Antipolis, France
| | - V Bourdès
- Evaluation Department-Cutis, Galderma R&D, Nestlé Skin Health, Sophia Antipolis, France
| | - C Marty
- Evaluation Department-Cutis, Galderma R&D, Nestlé Skin Health, Sophia Antipolis, France
| | - C Piketty
- Evaluation Department-Cutis, Galderma R&D, Nestlé Skin Health, Sophia Antipolis, France
| | - B Dréno
- Dermatology, CHU Nantes, CRCINA, University Nantes, Nantes, France
| |
Collapse
|
50
|
Corvec S, Dagnelie MA, Khammari A, Dréno B. Taxonomy and phylogeny of Cutibacterium (formerly Propionibacterium) acnes in inflammatory skin diseases. Ann Dermatol Venereol 2018; 146:26-30. [PMID: 30558958 DOI: 10.1016/j.annder.2018.11.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2018] [Revised: 10/08/2018] [Accepted: 11/14/2018] [Indexed: 01/01/2023]
Abstract
Since its discovery, Propionibacterium acnes has undergone various name changes, and has been known since 2016, as Cutibacterium acnes. Herein we set out the history and rational of these taxonomic changes together with a description of a new genus, Cutibacterium, which includes five species within the cutaneous ecosystem. Modern microbiological techniques allow finer distinction between species and subspecies while also enabling the identification of separate subtypes within the population of Cutibacterium acnes. Phylogeny and molecular typing techniques thus provide a better understanding of the subtypes involved in certain inflammatory skin diseases, including acne, folliculitis and progressive macular hypomelanosis.
Collapse
Affiliation(s)
- S Corvec
- Bacterial Department, Nantes University Hospital, CRCINA, université de Nantes, 44049 Nantes, France.
| | - M-A Dagnelie
- Dermatology Department, Nantes University Hospital, CRCINA, CIC 1413, université de Nantes, 44093 Nantes, France
| | - A Khammari
- Dermatology Department, Nantes University Hospital, CRCINA, CIC 1413, université de Nantes, 44093 Nantes, France
| | - B Dréno
- Dermatology Department, Nantes University Hospital, CRCINA, CIC 1413, université de Nantes, 44093 Nantes, France
| |
Collapse
|